Cigarette smoking and p16 ink4α gene promoter hypermethylation in non-small cell lung Carcinoma patients: A meta-analysis

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Zhang, Bo ^a   Zhu, Wei ^b   Yang, Ping ^a   Liu, Tao ^a,b,c   Jiang, Mei ^a   He, Zhi Ni ^a   Zhang, Shi Xin ^a   Chen, Wei Qing ^a   Chen, Wen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Guangdong Institute of Public Health   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DNA METHYLATION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MARKER GENE; P16 INK4ALPHA GENE; PROMOTER REGION; QUANTITATIVE STUDY; SMOKING HABIT; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; GENETICS; LUNG TUMOR; META ANALYSIS; MIDDLE AGED; PUBLISHING; SAMPLE SIZE; SMOKING;

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; SAMPLE SIZE; SMOKING;

EID: 83255181725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028882     Document Type: Article

References (63)

1. Ministry of Health of the People,s Republic of China (2008) The cause of death in China: the third retrospective sample survey Beijing Peking Union Medical College Press.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
4. Villeneuve PJ, Mao Y, (1994) Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health 85: 385-388.
5. Sun S, Schiller JH, Gazdar AF, (2007) Lung cancer in never smokers-a different disease. Nat Rev Cancer 7: 778-790.
6. Subramanian J, Govindan R, (2007) Lung cancer in never smokers: a review. J Clin Oncol 25: 561-570.
7. Toh CK, Lim WT, (2007) Lung cancer in never-smokers. J Clin Pathol 60: 337-340.
8. Belinsky SA, (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717.
9. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
10. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
12. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, et al. (2003) Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153-160.
13. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, et al. (2009) Methylated genes as new cancer biomarkers. Eur J Cancer 45: 335-346.
14. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, et al. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958.
15. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896.
16. Lu C, Soria JC, Tang X, Xu XC, Wang L, et al. (2004) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583.
17. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, et al. (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
18. Egger G, Liang G, Aparicio A, Jones PA, (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
19. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
20. Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, et al. (2001) Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 61: 2092-2096.
21. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, et al. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255.
22. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, et al. (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61: 3419-3424.
23. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, et al. (2002) Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res 93: 1107-1113.
24. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, et al. (2003) Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94: 589-592.
25. Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, et al. (2004) Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110: 462-464.
26. Kim JS, Kim H, Shim YM, Han J, Park J, et al. (2004) Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 25: 2165-2171.
27. Divine KK, Pulling LC, Marron-Terada PG, Liechty KC, Kang T, et al. (2005) Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 114: 400-405.
28. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P, (2006) Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8: 46-51.
29. Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, et al. (2006) The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106: 2190-2199.
30. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, et al. (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66: 1371-1375.
31. Georgiou E, Valeri R, Tzimagiorgis G, Anzel J, Krikelis D, et al. (2007) Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking. Eur J Cancer Prev 16: 396-402.
32. Guzman LM, Koriyama C, Akiba S, Eizuru Y, Castillo D, et al. (2007) High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res 40: 365-372.
33. Kim DS, Cha SI, Lee JH, Lee YM, Choi JE, et al. (2007) Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 58: 1-6.
34. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, et al. (2009) Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 30: 1132-1138.
35. Wang D, Wang J, Li Y, He Z, Zhang Y, (2010) The influence of anthracosis and p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcinoma. Exp Mol Pathol 90: 131-136.
36. Yanagawa N, Tamura G, Oizumi H, Endoh M, Sadahiro M, et al. (2011) Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res 31: 1211-1214.
37. Zhang CY, Jin YT, Xu HY, Zhang H, Zhang WM, et al. (2011) Relationship between promoter methylation of p16, DAPK and RAR beta genes and the clinical data of non-small cell lung cancer. Chin J Med Genet 28: 23-28.
38. Konno S, Morishita Y, Fukasawa M, Shu Y, Wang D, et al. (2004) Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. Cancer 102: 348-354.
39. Peng Z, Shan C, Wang H, (2010) [Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers]. J Cent South Univ (Med Sci) 35: 247-253.
40. Zochbauer-Muller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, et al. (2003) Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 107: 612-616.
41. Kim H, Kwon YM, Kim JS, Lee H, Park JH, et al. (2004) Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 22: 2363-2370.
42. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, et al. (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11: 1219-1225.
43. de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, et al. (2005) Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 50: 199-209.
44. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, et al. (2005) Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511.
45. Saatci C, Caglayan AO, Ozkul Y, Tahiri S, Turhan AB, et al. (2009) Detection of p16 promotor hypermethylation in "Maras powder" and tobacco users. Cancer Epidemiol 33: 47-50.
46. Brait M, Ford JG, Papaiahgari S, Garza MA, Lee JI, et al. (2009) Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev 18: 2984-2991.
47. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
48. Liu G, Zhou W, Christiani DC, (2005) Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 26: 265-272.
49. Sherr CJ, McCormick F, (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
50. Liggett WH Jr, Sidransky D, (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206.
51. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
52. Okano M, Bell DW, Haber DA, Li E, (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
53. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, et al. (2000) CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404: 1003-1007.
54. Belinsky SA, Nikula KJ, Baylin SB, Issa JP, (1996) Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA 93: 4045-4050.
55. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, et al. (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2291-2298.
56. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, et al. (2007) Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 55: 205-213.
57. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, et al. (2010) The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 120: 521-532.
58. Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, et al. (2002) The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene 21: 4822-4829.
59. Zhong L, Goldberg MS, Parent ME, Hanley JA, (2000) Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. Lung Cancer 27: 3-18.
60. Brennan P, Buffler PA, Reynolds P, Wu AH, Wichmann HE, et al. (2004) Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 109: 125-131.
61. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, et al. (2004) Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96: 99-106.
62. Kurahashi N, Inoue M, Liu Y, Iwasaki M, Sasazuki S, et al. (2008) Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 122: 653-657.
63. IARC (2004) International Agency for Research on Cancer: Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 83 Lyon IARC.